Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Nuclasta 60mg Injection
Manufacturer/Marketed By : CADILA PHARMACEUTICALS LTD
$196.76 $106.25
Nuclasta 60mg injection consists of the active ingredient Denosumab. It is a medication used to treat osteoporosis, characterised by weakened bones. It is also prescribed to prevent bone complications in...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
DENOSUMAB
Active Pharmaceutical Ingredient
Nuclasta 60mg Injection
$196.76
$106.25
Nuclasta 60mg injection consists of the active ingredient Denosumab. It is a medication used to treat osteoporosis, characterised by weakened bones. It is also prescribed to prevent bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases. Nuclasta 60mg Injection works by inhibiting a protein called RANK ligand, which plays a role in the breakdown of bone tissue. Studies proved it can significantly increase bone density, reducing fracture risk in postmenopausal women with osteoporosis and patients with cancer-related bone loss. Close monitoring of renal function may be necessary for patients with moderate renal impairment. Nuclasta 60mg injections should not be used in individuals with known hypersensitivity or allergic reactions to its components. Adequate calcium and vitamin D supplementation is required to ensure during the treatment. It is not approved for use in children and adolescents. Its safety and effectiveness in pediatric populations have not been established, so its use is contraindicated in individuals under 18. This medication should be used cautiously in individuals with pre-existing hypoparathyroidism, characterised by low parathyroid hormone levels.
Active Pharmaceutical Ingredient
Uses
• Osteoporosis
• Bone loss due to hormonal therapy in breast or prostate cancer
• Multiple myeloma (cancer affects plasma cells in the bone marrow)
• Bone metastases (cancer that spreads to bone)
Benefits
Nuclasta 60mg injection has therapeutic effects that include reducing fracture risk, increasing bone mineral density, and improving overall bone health. By inhibiting bone resorption through its action on RANK ligands, this medication helps to strengthen bones and decrease the likelihood of fractures in individuals with osteoporosis or those at high risk. It also increases bone mineral density, an important marker of bone strength. These therapeutic effects contribute to improved bone health and a reduced risk of fractures, ultimately enhancing the quality of life for patients.
Side Effects
Nuclasta 60mg Injection can cause side effects like all medications, although not everyone who takes it will experience them.
Most Common Side Effects
• Injection site reactions
• Back pain
• Musculoskeletal pain
• Infections
• Abdominal pain
• Headache
• Hypophosphatemia (low blood phosphate levels)
Common Side Effects
• Osteonecrosis of the jaw (severe necrosis or death of jaw cells)
• Atypical femoral fractures
• Hypocalcemia (low blood calcium levels)
How To Use
Nuclasta 60mg Injection is given as an injection by healthcare professionals. The dosage and duration of treatment will be based on the individual's condition and response to the medication and should be determined by a healthcare provider.
Safety Advice
• Breast Feeding: Whether Nuclasta 60mg Injection is excreted in milk is unknown. So it is better to consult a healthcare provider if you are a breastfeeding mother before taking this medication.
• Alcohol: It is generally recommended to avoid or limit alcohol consumption while taking Nuclasta 60mg Injection. Alcohol can interact with this medication, potentially increasing the risk of side effects.
• Liver: Nuclasta 60mg Injection is primarily metabolised in the liver, and its safety has not been extensively studied in individuals with severe liver impairment. It is crucial to communicate any pre-existing liver conditions or changes in liver function to your healthcare provider to ensure this medication's safe and effective use.
• Lungs: If you have a lung or respiratory disorders history, it is important to consult your healthcare provider before taking Nuclasta 60mg Injection.
• Driving: Patients receiving Nuclasta 60mg Injection should be advised to avoid driving or operating machinery if they experience side effects such as fatigue, dizziness, or blurred vision, impairing a patient's ability to drive or operate machinery safely.
• Pregnancy: The safety of using Nuclasta 60mg Injection during pregnancy has not been established. Limited studies are available regarding the use of this medication in pregnant women, so it is recommended to use caution and consult a doctor before considering its use during pregnancy.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.